Fall is in full swing here at BHE and we have a lot of exciting projects going on. We’ve also decided to mix up our Employee Spotlight feature so that you can get to know our employees a little bit better. This month we’re highlighting one of our new Instant Health Data (IHD) team members and recent PhD grad, Lauren Johns.
Researchers at Boston Health Economics, the Carolina Urologic Research Center, and Janssen, also found high hospitalization rates associated with metastatic prostate cancer. WALTHAM, MA, September 15, 2017 –—A new real-world evidence study shows that the development of prostate cancer metastasis was associated with a five-fold increase in medical costs at the time of diagnosis, and substantially higher costs thereafter. Published in the May issue of Cancer, the scientific journal of the American Cancer Society, the study, titled “Impact of Subsequent Metastases on Costs and Medical Resource Use for Prostate Cancer Patients Initially Diagnosed with Localized Disease,” was conducted by BHE, the Carolina Urologic Research Center (CURC), and Janssen. Cancer also published an editorial by Drs. Daniel Frendl and Aria Olumi that discusses the value of this study’s data in the same issue of the journal. The study, led by Drs. Tracy T. Li, PhD (Janssen), Neal D. Shore, MD, FACS…
Methodologists in the HEOR community have been busy over the past 9 months. In September 2016, the Second Panel on Cost-Effectiveness in Health and Medicine published a special communication in JAMA (and subsequent hardcover book) that sought to provide guidance for improving the quality of cost-effectiveness (CE) analyses. A few months later in February 2017, the Institute for Clinical and Economic Review (ICER) presented updates to its Value Assessment Framework, which contains its conceptual approach for conducting incremental cost-effectiveness analyses (CEAs). While ICER’s framework sets to guide their internal modeling efforts and makes no claims to influence general modeling principles, HEOR practitioners throughout the industry may turn to ICER’s framework for guidance especially as the organization gains national attention.
In early February, the Institute for Clinical and Economic Review (ICER) presented proposed updates to its Value Assessment Framework, based largely on stakeholder feedback received during a public comment period in late 2016. These updates focused on four domains of the framework: (1) comparative clinical effectiveness; (2) incremental cost-effectiveness analysis (CE); (3) other benefits or disadvantages; and (4) contextual considerations. While each domain is important, the incremental cost-effectiveness analysis has proved the most controversial. Since the current comment period is almost up, here’s my review of the updates to the CE framework.
As we make our way through the first quarter of 2017, there are a lot of exciting changes happening in the field of health economics and outcomes research (HEOR) that may have important implications for how researchers generate and disseminate evidence.
Early last month the Institute for Clinical and Economic Review (ICER) released a revised Value Assessment Framework for public comment based on feedback received from patients, clinicians, life science companies, and other stakeholders. While a majority of the proposed changes lacked real luster, there is one proposed change that pharma should take note of: ICER’s new method for estimating the cost-effectiveness (CE) threshold.
At BHE, we spend a lot of time speaking with leaders in the field of real world data about the ways in which they go about generating robust, reliable evidence for use with key stakeholders both internally and externally. Fundamentally, the unique way that companies combine database experts, processes, and technology provides the best indication of success. Below are a few of my thoughts on this topic based on conversations with our clients and industry stakeholders in 2016.
BHE’s team grew considerably over the past few months. Here’s a look at one of our newest team members, Dr. Rahul Jain:
Boston Health Economics (BHE), a 19-year-old healthcare analytics firm, is excited to celebrate greater industry use of our leading Instant Health Data platform, IHD. Over the past few years, IHD has been transforming the way researchers and analysts interact with real-world data for improved insights.